MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria collaborators at Seattle Children’s Research Institute report on safety and efficacy of early arresting, non-replicating, genetically attenuated malaria sporozoite vaccine.
In a publication in Science Translational Medicine, Sean Murphy, Stefan Kappe and colleagues at Seattle Children’s Research Institute (SCRI) report the safety and efficacy against controlled human malaria infection of the administration by mosquito bite of Plasmodium falciparum (Pf) parasites attenuated by deletion of three genes.
United to Beat Malaria and Shot@Life Delegation Visit Sanaria
On Thursday 28 July 2022, a team from the United Nations Foundation, including United to Beat Malaria and Shot@Life visited Sanaria Inc.
COLLABORATORS PUBLISH ARTICLE IN NATURE COMMUNICATIONS: PLASMODIUM FALCIPARUM 7G8 CHALLENGE PROVIDES CONSERVATIVE PREDICTION OF EFFICACY OF PFNF54-BASED PFSPZ VACCINE IN AFRICA
ROCKVILLE, MD, USA – July 12, 2022 – Sanaria Inc., University of Maryland School of Medicine, Naval Medical Research Center, National Institutes of Health (USA), University of Bamako Malaria Research and Training Center (Mali), and University of Tübingen (Germany) published results in Nature Communications showing Plasmodium falciparum 7G8 human challenge trials provide a conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa.
Prince Ned Nwoko Foundation Visits Sanaria
On Tuesday, June 21st 2022, Sanaria was pleased to welcome Prince Ned Nwoko (virtually) and Mr. Chuks Anyaduba to Sanaria to discuss future interactions. Sanaria looks forward to a long a fruitful partnership as we push together towards our shared goal of a PfSPZ vaccine that will help to eliminate malaria. Please see link for Prince Ned Nwoko Foundation’s press release on this visit.
Sanaria Announces the Start of Clinical Trials of its PfSPZ Vaccines in Mali and Indonesia
Sanaria Inc. announces that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.
Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa
Controlled human malaria infection (CHMI) with a Brazilian parasite highly divergent from vaccine and field strains provided stringent estimates of vaccine efficacy in Mali, Africa, and could replace field testing, streamlining vaccine development.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.